Roche and Boehringer Ingelheim metabolic health candidates
Discussed in 1 analyzed podcast episode across 1 show
Discussed On
Episodes
The Top Line · Jul 10, 2026
A $10B deal, China trial scrutiny and highlights from ADA 2026
Vertex Crinetics acquisition and rare endocrine disease expansionClinical trial regulation and China data integrity scrutinyGLP-1 agonist efficacy and weight loss outcomesRetatrutide triple agonist development and comorbidity benefitsOral obesity medication market competition and prescriptions
View Analysis